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Introduction: A hallmark of systemic autoimmune diseases like systemic lupus erythematosus (SLE) is the increased
expression of interferon (IFN) type I inducible genes, so-called IFN type I signature. Recently, T-helper 17 subset
(Th17 cells), which produces IL-17A, IL-17F, IL-21, and IL-22, has been implicated in SLE. As CCR6 enriches for Th17 cells,
we used this approach to investigate whether CCR6+ memory T-helper cells producing IL-17A, IL-17F, IL-21, and/or
IL-22 are increased in SLE patients and whether this increase is related to the presence of IFN type I signature.
Methods: In total, 25 SLE patients and 15 healthy controls (HCs) were included. SLE patients were divided into IFN type
I signature-positive (IFN+) (n = 16) and negative (IFN−) (n = 9) patients, as assessed by mRNA expression of IFN-inducible
genes (IFIGs) in monocytes. Expression of IL-17A, IL-17F, IL-21, and IL-22 by CD4+CD45RO+CCR6+ T cells (CCR6+ cells)
was measured with flow cytometry and compared between IFN+, IFN− patients and HCs.
Results: Increased percentages of IL-17A and IL-17A/IL-17F double-producing CCR6+ cells were observed in IFN+
patients compared with IFN− patients and HCs. IL-17A and IL-17F expression within CCR6+ cells correlated significantly
with IFIG expression. In addition, we found significant correlation between B-cell activating factor of the tumor necrosis
family (BAFF)–a factor strongly correlating with IFN type I − and IL-21 producing CCR6+ cells.
Conclusions: We show for the first time higher percentages of IL-17A and IL-17A/IL-17F double-producing CCR6+
memory T-helper cells in IFN+ SLE patients, supporting the hypothesis that IFN type I co-acts with Th17 cytokines in SLE
pathogenesis.Introduction
Systemic lupus erythematosus (SLE) is a debilitating sys-
temic autoimmune disease characterized by the production
of autoreactive antibodies and multiorgan inflammation [1].
A hallmark of systemic autoimmune diseases is the in-
creased expression of interferon (IFN) type I in both blood
and disease-affected tissues [2]. About half of the SLE pa-
tients exhibit an IFN type I signature or upregulation of
IFN type I-induced genes (IFIGs), which have been found
to correlate with disease activity and severity [3-5].
Another key factor in the pathogenesis of SLE, apart
from IFN type I, is interleukin-17A (IL-17A) [6-9]. IL-17A* Correspondence: e.lubberts@erasmusmc.nl
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reproduction in any medium, provided the oris produced by several immune cell types, including CD4+
T cells (Th17 cells), CD8+ T cells, CD4-CD8-CD3+
(double-negative, DN) T cells, natural killer cells, γδ-T
cells, and mast cells [10,11]. Naïve CD4+ T cells differenti-
ate to Th17 cells under the influence of IL-6 and TGF-β
[12]. The expansion and stability of the Th17 population is
regulated by IL-21 and IL-23, respectively [13,14]. C57BL/
6-lpr/lpr mice that lack IL-23 receptor signaling are pro-
tected for SLE development [15]. In SLE patients, in-
creased plasma levels of IL-17A correlate with disease
activity (SLEDAI) [6]. In addition, in peripheral blood of
SLE patients, an increased number of IL-17-producing
cells is observed. These cells correlate with disease activity
and decrease with treatment [7,8]. IL-17-producing cells
have also been found in several affected organs of SLE pa-
tients [7,9].
Co-activity between IFN type I and IL-17/Th17 cells
has been suggested in autoimmune diseases [16,17]. Ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mouse model for multiple sclerosis (MS), IFN type I treat-
ment caused exacerbation if the disease was Th17 driven
but was effective if the disease was Th1 driven [17]. In the
same study, MS patients that did not respond to IFN type
I therapy had higher serum levels of IL-17A before therapy
onset [17]. These two observations suggest additional ef-
fects of the IFN type I and Th17 system co-acting in the
pathogenesis of autoimmune diseases.
Co-activity of IFN type I and Th17 pathways has also
been suggested for SLE by the Ro52/TRIM21−/− mouse
model. Ro52/TRIM21 is involved in the ubiquitination of
interferon regulatory factors (IRFs), a process that limits
the IFN type I response [18]. After ear tagging, Ro52/
TRIM21−/− mice develop an SLE-like phenotype [19]. Inter-
estingly, when these mice are crossed on an IL-23p19−/−
mouse line, they do not develop SLE, indicating that the de-
velopment of an SLE phenotype through enhanced IFN
type I production in these mice is dependent on the IL-17/
Th17 pathway.
Yet another important factor involved in the pathogen-
esis of SLE is B cell-activating factor of the tumor necrosis
factor family (BAFF). BAFF transgenic mice develop
lupus-like disease [20], and increased expression of BAFF
protein has been found in SLE patients, correlating with in-
creased disease activity [21-23]. We previously described a
strong correlation between BAFF mRNA expression in
monocytes and the IFN type I signature in primary Sjögren
syndrome (pSS) patients [24]. Interestingly, IL-21, a cyto-
kine produced by Th17 cells, in combination with BAFF,
has been reported to induce synergistically the differenti-
ation of human memory B cells into antibody-producing
plasma cells in the absence of further co-stimulation [25].
BAFF is known to be involved in germinal center formation
[26], a process in which IL-17 is also involved [27].
The previously mentioned literature suggests an asso-
ciation between the pathogenic IFN type I and Th17
pathways. So far, no studies have been performed on the
co-occurrence of these pathogenic pathways in SLE pa-
tients. In this study, we report for the first time a higher
percentage of IL-17A and IL-17A/F producing CCR6+
T-memory cells in IFN type I-positive SLE patients.
Moreover, BAFF gene expression in monocytes corre-
lates significantly with IL-21 expression in these CCR6+
cells, supporting the concept of co-activity of IFN type I,
Th17, and BAFF in the pathogenesis of SLE.
Methods
Patients
The 25 patients fulfilling the American College of Rheuma-
tology revised criteria for SLE [28] were recruited at the
outpatient clinic of the Immunology Department and the
Rheumatology Department of the Erasmus Medical Center
Rotterdam. The level of disease activity was assessed byusing the SLEDAI [29]. Fifteen healthy controls (HCs), nei-
ther with autoimmune diseases nor using corticosteroids,
were included. Characteristics of patients and controls are
summarized in Table 1. The Medical Ethical Review Com-
mittee of the Erasmus MC approved the study, and written
informed consent was obtained.
Blood collection and isolation of monocytes
Blood was collected in clotting tubes for serum prepar-
ation (stored at −80°C) and in sodium-heparin tubes for
peripheral blood mononuclear cell (PBMC) preparation,
as described previously [30]. CD14-positive monocytes
were isolated as described [30].
RQ-PCR
Total RNA was isolated from purified monocytes followed
by cDNA preparation and real-time quantitative polymer-
ase chain reaction (RQ-PCR) analysis by using prede-
signed primer/probe sets (Applied Biosystems) [30]. For
calculation of relative expression, all samples were normal-
ized against expression of the household gene Abl [31].
Fold-change values were determined from normalized CT
values by using the 2-ΔΔCT method (User Bulletin; Applied
Biosystems, Foster City, CA, USA).
Flow cytometry
PBMCs were restimulated, stained, and measured with flow
cytometry, as previously described [32]. For extracellular
staining, CD4, CD45RO, and CCR6 monoclonal antibodies
were obtained from BD Biosciences (San Diego, CA,
USA), and CD25 antibodies from Biolegend Inc. (San
Diego, CA, USA). For intracellular staining, IL-17A,
IL-17F, IL-21, and IL-22 monoclonal antibodies were
obtained from eBioscience, and IL-17A monoclonal
antibodies from Biolegend Inc. Samples were measured
on a FACScantoII flow cytometer (BD Biosciences).
Analysis was performed by using FlowJo v7.6 research
software (Tree Star Inc. Ashland, OR, USA).
Factor analysis
The expression levels of 11 IFN type I-inducible genes (pre-
viously found to be increased in SLE) were submitted to a
principal component analysis to identify correlated groups
of genes to reduce data complexity. Kaiser-Meyer-Olkin
measure of sampling adequacy was 0.839 with a significant
Bartlett test of sphericity (P < 0.001). Eigenvalues were de-
rived to assess the amount of variance explained by each
component factor.
Statistical analyses
Statistical analyses were performed by using the SPSS 20.0
package. When data were not normally distributed, values
were expressed as medians with interquartile ranges (IQRs),
and comparisons were made by using the nonparametric
Table 1 Demographics and clinical characteristics of participants
Variable SLE patients Healthy controls
(n = 25) (n = 15)
IFN type I negative IFN type I positive
(n = 9) (n = 16)
Demographics
Number of females, n (%) 9/9 (100%) 14/16 (88%) 15/15 (100%)
Age (years) 41.3 ± 17.5 39.8 ± 15.7 41.0 ± 14.0
Race, n (%)
Caucasian 8/9 (89%) 7/16 (44%) 15/15 (100%)
Black 0/9 (0) 8/16 (50%) 0/15 (0)
Asian 0/9 (0) 0/16 (0) 0/15 (0)
Mixed race 1/9 (11%) 1/16 (6%) 0/15 (0)
Clinical
Disease duration (years) 12.1 ± 8.0 14.4 ± 11.3 -
Mucocutaneous, n (%) 3/9 (33%) 10/16 (63%) -
Arthritis, n (%) 7/9 (78%) 6/16 (38%) -
Serositis, n (%) 1/9 (11%) 3/16 (19%) -
Nephritis, n (%) 3/9 (33%) 9/16 (56%) -
Neuropsychiatric, n (%) 1/9 (11%) 3/16 (19%) -
Hematologic, n (%) 6/9 (67%) 12/16 (75%) -
Laboratory
ANA positivity, n (%) 9/9 (100%) 16/16 (100%) -
Anti-ds-DNA positivity, n (%) 5/9 (56%) 10/16 (63%) -
Treatment
Hydroxychloroquine, n (%) 7/9 (78%) 11/16 (69%) -
Corticosteroids, n (%) 5/9 (56%) 10/16 (63%) -
Mycophenolate mofetil, n (%) 0/9 (0) 4/16 (25%) -
Azathioprine, n (%) 2/9 (22%) 3/16 (19%) -
Cyclophosphamide, n (%) 0/9 (0) 1/16 (6%) -
Values are the mean ± SD, median (25% quartile,75% quartile) or number (%) of patients, depending on whether the data are continuous or dichotomous, and
whether the data are normally distributed or not.
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the nonparametric Kruskal-Wallis test was performed. Cor-
relations were assessed by using either the Pearson correl-
ation test for normally distributed data or Spearman rho
when data were not normally distributed. Differences were
considered statistically significant if P < 0.05.
Results
Prevalence of the IFN type I signature in SLE patients
In monocytes of 25 SLE patients and 15 HCs, we assessed
the expression levels of 11 IFIGs previously assessed in
monocytes from patients with primary Sjögren syndrome
(pSS) (IFI27, IFI44L, IFIT3, IFITM1, SERPING1, IFIT1,
IFIT2, LY6E, IFI44, XAF1, and MXA) [24], and the ex-
pression of which was also found to be increased in SLE
patients [2,3,33,34]. To reduce data complexity, expressionlevels of the 11 genes were submitted to a principal com-
ponent analysis to identify correlated groups of genes. The
results of the principal component analysis identified a
subset of four genes (IFI44L, IFITM1, SERPING1, and
LY6E) to explain 95% of the total variance of the 11 IFN
type I-inducible genes within the SLE cohort. Given that
the expression of these four IFN type I-inducible genes
was not normally distributed, log transformations of ex-
pression values were performed, and IFN scores were cal-
culated as described for pSS [24]. MeanHC and SDHC of
each gene in the HC-group were used to standardize ex-
pression levels. IFN scores per subject represent the sum
of these standardized scores. When we set the threshold
for a positive IFN type I signature at IFN score of 8 [24],
64% of SLE patients displayed an IFN type I signature, and
one of the 15 HC subjects (7%) (Figure 1A,B).
Figure 1 Prevalence of IFN type I signature in SLE patients. (A) Heatmap showing gene expression of four IFN type I-inducible genes in
monocytes of SLE patients (n = 25) and HCs (n = 15). On the left, the HCs are depicted, and on the right, the SLE patients are depicted and
subdivided into IFN type I signature-positive and -negative patients. Red indicates high gene expression, and cases are depicted according to IFN
scores. (B) Distribution of IFN scores in IFN type I signature-positive and -negative patients and HCs. In red, IFN type I-positive cases are depicted.
Blue lines represent medians. P values are shown, and to compare medians, the Mann–Whitney U test was used.
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percentages of IL-17A, IL-17F, and IL-21 producing
CCR6+ cells
Because CCR6 enriches for Th17 cells [35-37], CCR6+
cells were selected after gating on lymphocytes and
memory Th cells (CD4+CD45RO+ cells) within PBMCs
and after CD25+ cells were excluded. To investigate
whether the IFN type I signature is associated with an
increase in Th17 cytokines expressed by memory CCR6+
T cells, we measured the percentages of IL-17A, IL-17F,
IL-22 and IL-21 producing CCR6+ T memory cells in SLE
patients positive for the IFN type I signature (IFN+) and
patients negative for the signature (IFN−) and HC. The
percentages of CCR6+ cells within the CD4+CD45RO+ T-
cell population and within total lymphocytes were com-
parable between the three studied groups (data not
shown). Interestingly, the percentages of CCR6+IL−17A+
cells were significantly increased in IFN+ patients, as com-
pared with IFN− patients (P = 0.03), and a higher trend
was observed compared with HCs (P = 0.07) (Figure 2A).
The percentages of CCR6+IL−17F+ and, in particular, the
IL-17A/IL-17F double producers were significantly in-
creased in the IFN+ group compared with HC (P = 0.009)
(Figure 2B, and see Additional file 1: Figure S1). The per-
centages of CCR6+IL−22+ cells showed a higher trend forIFN+ versus IFN− patients (P = 0.06) and IFN+ patients ver-
sus HC (P = 0.09) (Figure 2C). The percentages of IL-21
expressing CCR6+ cells were also significantly increased in
IFN+ patients compared with IFN− patients (Figure 2D).
These data suggest an association between the presence of
the IFN type I signature and the expression of Th17 cyto-
kines in SLE.
In addition, we investigated whether the Th17 cytokine
production is associated with disease activity as assessed by
SLEDAI scores. No significant correlations were observed
between the SLEDAI scores and IL-17A and/or IL-17F ex-
pression (data not shown). Except for race, no differences
in demographic, clinical, or laboratory data were found be-
tween IFN+, IFN− SLE patients and/or HCs (Table 1).
BAFF mRNA expression is correlated with IL-21 expression
within CCR6+ memory T cells
Correlating the expression of IFIGs (as reflected by the
total IFN score) with other parameters assessed in this
study, we observed a significant positive correlation be-
tween the expression of IL-17A and IL-17F within CCR6+
cells and IFIG expression (Figure 3A,B). Also in this SLE
cohort, IFIG expression correlated strongly with the BAFF
mRNA expression in monocytes (r = 0.527; P < 0.0001)


























































Figure 2 SLE patients with IFN type I signature show higher percentages of IL-17A and IL-17A/IL-17 F producing CCR6+ cells. (A-D).
Proportions of IL-17A (A), IL-17 F (B), IL-22 (C), and IL-21 (D) expressing cells within CCR6+ memory T-cell population in PBMCs of IFN− (n = 9) and
IFN+ (n = 16) patients and HC (n = 15). All proportions were measured by intracellular flow cytometry. Horizontal line indicates median.
*P < 0,05; **P < 0,01; to compare means, a Kruskal-Wallis test was used followed by Mann–Whitney U test.
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find a significant correlation between BAFF mRNA and
the percentages of IL-21 producing CCR6+ cells (r = 0.406;
P = 0.010) (Figure 3D). Both BAFF and IL-21 are involved
in the selection and activation of B cells, which is crucial
in the pathogenesis of SLE, indicating that downstream
factors of the IFN type I and Th17 pathways might also be
associated.Discussion
Here we show for the first time a co-occurrence of in-
creased IFN type I activity and increased IL-17/Th17 sys-
tem in SLE patients. We found increased percentages of
IL-17A, IL-17A/IL-17F, and IL-21 producing CCR6+ T
memory cells in IFN type I-positive SLE patients. This
finding further strengthens the hypothesis that IFN type I
and Th17 cells, by co-acting, contribute to the pathogen-
esis of SLE. Further research to understand the link be-
tween these two pathways is warranted.A possible mechanism explaining the co-occurrence of
IFN type I and IL-17/Th17 immune pathway in SLE could
be that both IFN type I and production of IL-6 and IL-23
by DCs are regulated through IRF-5 [38,39]. Activation of
TLR signaling on DCs will then lead to simultaneous en-
hancement of both pathways. Evidence suggests that TLR7
activation of plasmacytoid DCs, the main producers of IFN
type I, promotes and modifies Th17 cell differentiation and
function [40]. IFN type I itself is also able to promote Th17
differentiation and IL-17 production through induction of
STAT-3 in T cells and IL-6 in DCs [41,42]. In addition, IFN
type I-conditioned monocytes differentiate into DCs, driv-
ing the development of Th17 cells from autologous naive
CD4+ T cells [43].
In addition to the direct effect of IFN type I on Th17
cells, IFN type I may also act indirectly through the pro-
duction of BAFF. BAFF is reported to be involved in DC
maturation and DC-driven Th17 cell differentiation
in vitro [44]. BAFF gene silencing ameliorated joint path-
ology and inhibited the generation of Th17 cells in the

































































Figure 3 BAFF mRNA expression is correlated with IL-21 expression within CCR6+ memory T cells. (A) Correlation between IFN score and
IL-17A expression within CCR6+ memory T cells in SLE patients (n= 25). (B) Correlation between IFN score and IL-17 F expression within CCR6+ memory T
cells in SLE patients (n= 25). (C) Correlation between monocyte BAFF mRNA expression and IFN score in SLE patients and HCs (n= 40). (D) Correlation
between monocyte BAFF mRNA expression and IL-21 expression within CCR6+ cells in SLE patients and HCs (n= 40). The correlation coefficients (r) and P
values are shown. For correlations, the Spearman rho correlation test was used in (A), (B), and (D), and the Pearson correlation test was used in (C).
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[44]. In turn, IL-17A can induce the formation of neutro-
phil extracellular traps (NETs) [45], which could poten-
tially provide new autoantigens to active TLRs on DCs,
thereby forming a proinflammatory loop.
We find a correlation between BAFF, an IFN type I in-
ducible factor, and the Th17 produced cytokine IL-21.
Ettinger et al. [25] showed that IL-21 together with BAFF
promotes B-cell responses by bypassing the need for T-
cell help or TLR signaling. As these downstream factors
are both involved in activation and selection of B cells,
these findings again support the concept that IFN type I
and the Th17 pathway act together in driving the disease
process of SLE.
IL-21 is also produced by T follicular helper (Tfh) cells,
and production by Tfh is crucial for B-cell immunity. By
gating for CCR6 expression, we exclude the Tfh cells from
our analysis. We therefore measured the production of IL-
21 by total memory T cells (CD4+CD45RO+), which in-
clude the Tfh cells. The expression of IL-21 by these cells
is significantly increased in IFN+ patients compared with
IFN− patients and HCs, and IL-21 expression by memory
cells also strongly correlated with IFN score (data not
shown). These data suggest that Tfh effector function mayalso be increased in IFN+ patients; however, further studies
are required.
By gating on CCR6+ cells, we may miss certain IL-
17A-producing cells, including Tfh cells. However, the
percentages of IL-17A, IL-17F, and IL-22-producing
cells within the CCR6− population were 10– to 20-fold
lower than in the CCR6+ population, as described previ-
ously by Acosta-Rodriguez et al. [35]. In addition, we did
not find a difference in cytokine production between the
groups when gating on total CD4+CD45RO+ memory T
cells, possibly because the percentages are very small.
In contrast to others, we did not find a correlation be-
tween SLEDAI and Th17 cytokines [6]. This might be due
to the relatively low patient number, which is a limitation
of our study.
In addition to flow-cytometry analysis of cytokine ex-
pression by PBMCs, we also measured cytokine levels in
the serum of the participants in this study (data not
shown). Unfortunately, we were unable to detect IL-17A
and F in most of the samples. We did find IL-22 in serum
samples of all subjects, but they were not different be-
tween the groups. We also found higher levels of IL-21 in
IFN+ patients compared with IFN− patients and HCs, but
we could detect IL-21 in only one third of the samples.
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IFN type I and the Th17 pathway, our findings provide
the first support for co-occurrence of increased IFN
type I activity and increased IL-17/Th17 system in
SLE. The Th17-IFN type I interaction found in this study
might have implications for future treatment of SLE and
other systemic autoimmune diseases in which IFN type I
plays a role. Preliminary results from a phase IIa trial with
human IgG1κ anti-IFNα antibody, in 87 SLE patients,
showed so far a 40% reduction in IFN type I-induced gene
expression but no clinical effect compared with placebo
(abstract; Merrill J et al.a). Our data indicate that IFN type
I might act in concert with Th17 cytokines, paving the
way for combination therapies, possibly resulting in more
significant clinical effects in the future.
Conclusion
The aim of this study was to investigate whether CCR6+
memory T-helper cells and their cytokine expression
was increased in SLE patients. In addition, we exam-
ined whether this increase is related to the presence
of IFN type I signature. In the present study, we
showed that IFN+ patients had an increased percentage
of IL-17A and IL-17A/IL-17F double-producing CCR6+
memory T helper cells in the blood compared to IFN
negative patients and HCs. Interestingly, the IL-17A
and IL-17F expression within the CCR6+ cells corre-
lated significantly with IFIG expression. Moreover,
monocyte BAFF expression in these patients correlated
significantly with IL-21 producing CCR6+ memory T-
helper cells.
Thus, this study adds new insight into the co-
occurrence of the two pathogenic pathways in SLE, the
IFN type I and the Th17 pathway, and showed for the
first time a higher percentage of IL-17A and IL-17A/
IL-17F double-producing CCR6+ memory T-helper
cells in IFN+ SLE patients. These findings indicate that
IFN type I co-acts with Th17 cytokines in SLE patho-
genesis, and further functional studies, including un-
derstanding the mechanism, are warranted.
Endnote
aJ. Merrill, V. Chindalore, J. Box, N. Rothfield, J.
Fiechtner, J. Sun, D. Ethgen. Results of a randomized
placebo-controlled, phase 2a study of sifalimumab, an
anti-interferon-alpha monoclonal antibody, adminis-
tered subcutaneously in subjects with systemic lupus er-
ythematosus [abstract]. [2011] [THU0411].
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